Henry James International Management Inc. Trims Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Henry James International Management Inc. decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 16.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,851 shares of the biotechnology company’s stock after selling 3,500 shares during the quarter. Henry James International Management Inc.’s holdings in Ascendis Pharma A/S were worth $2,458,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP grew its position in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the period. Janus Henderson Group PLC grew its position in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares during the period. Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the third quarter worth about $60,000. Finally, ARS Investment Partners LLC boosted its stake in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after buying an additional 2,369 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND opened at $156.58 on Friday. The company has a market capitalization of $9.50 billion, a price-to-earnings ratio of -22.05 and a beta of 0.64. The business has a 50 day moving average price of $136.11 and a two-hundred day moving average price of $134.00. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $157.49.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. Equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on ASND. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Oppenheimer cut their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.